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Angiogenesis, the process of formation of new vessels, is fundamental in many biological 
processes including development, reproduction and wound repair. In tumor biology, key 
biochemical questions remain to be answered, in particular the molecular and cellular 
mechanisms responsible for establishing melanoma new vessels. The search of role for 
already identified soluble factors in experimental cell models encompassing brain 
endothelial cells, murine melanoma cell lines and pericytes could expand our molecular 
understanding of cerebral melanoma proliferation. The purpose of this chapter is to 
summarize existing knowledge of biochemical mechanisms of melanoma adhesion and 
angiogenesis, as well as new experimental data on the enzymatic and signaling cross-talk 
between tumor and microvascular cells. 
2. Mechanisms of melanoma adhesion and transendothelial migration  
During hematogeneous metastasis the blood borne malignant cells must successfully arrest 
in the microcirculation, invade the endothelium and escape from the vascular system. The 
process of extravasation (formation of dynamic, F-actin-rich pseudopodia that penetrate 
capillary endothelial walls) occurs when malignant cells, adherent to vascular endothelial 
cells (ECs), cause retraction of these cells and exposure of the underlying basal lamina. 
Models to studying the interaction between malignant cells and normal endothelium have 
been developed in vitro, using monolayers of vascular ECs, monolayers of vascular ECs on 
smooth muscle cell multilayers, or multicell biological membranes such as chorioallantoic or 
amniotic membranes (Nicholson, 1982). 
Initial interactions of highly metastatic tumor cells with ECs cause morphological changes in 
ECs and involve mechanical contact and transient adhesion, mediated by endothelial 
selectins and their ligands on the neoplastic cells. This contact initiates a sequence of 
activation pathways that involves cytokines, growth factors, bioactive lipids, and reactive 
oxygen species produced by either the cancer cells or the endothelium. These molecules 
elicit expression of integrin adhesion molecules in cancer cells and ECs, matrix 
metalloproteinases, and chemotactic factors that promote, by gradient, the attachment of 
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tumor cells to the vessel wall and/or transvascular penetration. Induction of endothelial free 
radicals can be cytotoxic to cancer cells. Afterwards, the adhesion of tumor cells to 
endothelial basal lamina, where they rapidly spread by solubilizing the protein structure, 
appears to be mediated by specific cell molecules such as fibronectin, laminin, collagen and 
glycosaminoglycans. Considerable information on the regulation of the adhesive and 
migratory properties of melanoma cells on the endothelial floor is available (Cangara et al., 
2010; Klemke et al., 2007). 
2.1 Integrins 
Several modes of integrin-mediated interaction between melanoma cells and ECs have been 
documented, e.g. between LFA-1 (αLβ2), VLA-4 (α4β1), and α4β7 on melanoma cells and 
their major receptors, ICAM-1, VCAM-1, and MAdCAM-1, respectively, on ECs. Adhesion 
of integrin/CD44 to hyaluronan is also important for the extravasation of melanoma cells 
into tissues. Therefore, not only the combination of chemokine receptors, but also adhesion 
molecules expressed on melanoma cells can determine their selective migration toward a 
particular site. Integrins are a superfamily of transmembrane heterodymeric (α and β 
subunits) surface receptors involved in cell-matrix and cell-cell adhesion. So far, at least, 18 
α subunits and 8 β subunits have been isolated and characterized. Metastatic melanoma 
cells do express multiple adhesion receptors which can be either extremely specific for a 
single ligand or capable of binding multiple ligands. It is likely that the tumor cell’s 
repertoire of adhesion receptors may influence not only its adhesive properties, but its 
metastatic characteristics as well. α6β1 integrin is expressed on the highly metastatic cell line 
B16/129 melanoma (Ruiz et al., 1993). It was suggested that α6 integrins play a dual role in 
the metastatic process, mediating the adhesion of tumor cells to the luminal surface of the 
endothelium and the adhesion to laminin in the subendothelial extracellular matrix (ECM) 
during extravasation. Malignant phenotype of melanoma cells expresses a melanoma-
specific integrin (α7β1) that binds laminin and is not detectable in normal melanocytes 
(Kramer et al., 1991). 
The expression of several cell adhesion molecules, notably vitronectin binding receptor αvβ3, 
has been associated with the metastatic potential of tumor cells. Confocal microscopy revealed 
the presence of the integrin αvβ3 on melanoma membrane protrusions and pseudopods 
penetrating the endothelial junction. αvβ3 was also enriched in heterotypic contacts between 
ECs and melanoma cells (Voura et al., 2001) (Fig. 1). However, many human melanoma cells 
do not express β3 integrins. Human melanoma cells with different metastatic potency, 
which do not express β2 or β3 integrins, express the VCAM-1 receptor α4β1. VCAM-1 is up-
regulated on activated ECs and promotes transendothelial migration (Klemke et al., 2007). 
On the other hand, α6β1 and α6β4 integrins are present at a high level on the luminal and 
basolateral side of vascular endothelium. Human melanoma cell lines that express high 
constitutive levels of the metastasis-associated marker ICAM-1 were found to secrete IL-1 in 
vitro. The IL-1 present in melanoma-conditioned medium induced the expression of VCAM-
1, endothelial-leukocyte adhesion molecule 1, and ICAM-1 on ECs in culture, and increased 
the rate at which melanoma cells and ECs adhered to each other (Burrows et al., 1991). 
2.2 Signal transduction 
Tumour cell transition from fluid to initial adhesive conditions to the endothelium involves 
an early polarization event and major rearrangements of the submembrane cytoskeleton 
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that remain poorly understood. PKC is involved in the metastatic characteristics of 
melanoma cells. Among PKC isoforms, the α isoform is postulated to increase motility of 
melanoma cells (Oka & Kikkawa, 2005). Reduced PKCβ and increased PKCζ and 
PKCι expression, at both protein and mRNA levels in melanoma cell lines, was found (Voris 
et al., 2010). As a molecular mechanism for enhancement of invasion, PKC was proposed to 
mediate the signal of 12-(S)-hydroxyeicosatetraenoic acid (HETE), a 12-lipoxygenase 
metabolite of arachidonic acid, that upregulates expression of integrin molecules. In 
metastatic melanoma cells, misregulated expression of PKCα and PKCδ, and elevated Src 
activity are required for efficient αvβ3-mediated invasion. 
Activation of signal transduction through the PKC/MEK/ERK during melanoma cell line 
B16BL6 cell invasion and metastasis has been reported (Tsubaki et al., 2007). In this context, 
results of Sandoval et al. (2001) suggest a critical role for Ca2+ signaling and activation of 
PKCα in mediating the disruption of VE-cadherin junctions, and thereby in the mechanism 
of increased endothelial permeability (Fig. 1). 
In integrin-ECM interactions, downstream signaling events include Ras, phosphatidylinositol-
3 kinase (PI3K), MAP kinases, FAK, Src, Akt, Abl and Rac, Rho and cdc42 small GTPases. 
Signaling pathway via α5β1 and αvβ3 integrins may be mediated by cross-talk with receptor 
tyrosine kinases associated with growth factor ligands (Soung et al., 2010). Overexpression 
of the small GTPase, RhoC, in various human cancers has been correlated with high 
metastatic ability and poor prognosis. Rho-kinase (ROCK) is an important effector of Rho 
GTPases. The oncogenic serine/threonine kinase Akt is a downstream effector of PI3K. Akt 
activation contributes to the neoplastic phenotype by promoting cell cycle progression, 
increasing antiapoptotic functions, and enhancing tumor cell invasion. Using a human 
melanoma cell line WM35, results suggest that RhoC promotes invasion in part via 
activation of the PI3K/Akt pathway, in a manner independent of ROCK signaling (Ruth et 
al., 2006). In addition, PKCα and Src enhance αvβ3-mediated invasion in part by increasing 
the GTPase activity of Rac relative to RhoA. PKCα influences focal adhesion formation, 
while PKCδ controls stress fibers (Putman et al., 2009). PKC interacts with Rho GTPases in 
the regulation of the actin cytoskeleton. The PKC-α isozyme binds the Rho GTPase cdc42, 
and both are coordinated with the Rac-PI3K signaling pathway in melanoma cell invasion 
and migration on extracellular matrix proteins (Byers et al., 2010). 
Transendothelial migration (TEM) is blocked by pharmacological inhibitors of Src family 
protein-tyrosine kinases (PP2 and herbimycin A), PI3K (wortmannin), and 
phosphatidylinositol-specific phospholipase C (U73122). These data indicate that there are 
signaling pathways for TEM independent of chemokine attraction, but through adhesion 
molecules including CD44 (Katakai et al., 2002). Integrins regulate cell adhesion process 
partially through control of extracellular signal-regulated kinases 1 and 2 (ERK1/2). In 
mutant B-Raf-expressing melanoma cells (SKMEL-24 and SKMEL-28), the ERK1/2 pathway 
was constitutively active, and ECM adhesion-dependent regulation of ERK1/2 activity was 
by-passed. Furthermore, in melanoma cells, ERK1/2 translocates to the nucleus and regulated 
transcription events in an adhesion-independent manner (Conner et al., 2003). On the other 
hand, PI3 kinase/Akt pathway is downstream of the major vascular endothelial growth 
factor (VEGF) receptors in endothelial cells, and it is activated in EC migration process in 
response to tumor efferent stimulation (Anfuso et al., 2009; Brader & Eccles, 2004) (Fig. 1). 
Contact of melanoma cells to HUVEC triggered rapid endothelial [Ca2+]i response through 
PLC-IP3 pathway. In addition, alternation of endothelial adherens junctions following 
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contact of melanoma cells was evidenced by changes in immunological staining patterns of 
vascular endothelial (VE)-cadherin. Inhibition of PI3K resulted in a reduction of melanoma 
cell transmigration (Peng et al., 2005). 
 
 
Fig. 1. Cell surface interactions and cellular responses between melanoma cells and 
endothelial cells (ECs), and ECs–ECs in blood vessels. During dissemination of malignant 
cells, the attachment of cancer cells to the ECs on microvasculature is considered to be an 
essential step. A spectrum of growth factors/chemokines is able to induce intracellular 
signaling responses in both ECs and melanoma cells which reciprocally secrete similar 
autocrine and paracrine growth factors and chemokines. Signaling responses include 
functional cross-talk between growth factor/growth factor receptors and integrins, and 
actin/myosin cytoskeleton reorganization. ECs exploit cytoskeletal elements to ensure the 
integrity of the cell monolayer in quiescent endothelium, and to enable the disintegration of 
the former barrier in response to various agonists. Functional association between VEGFR2 
and integrin αvβ3 is of reciprocal nature since each receptor is able to promote activation of 
its counterpart. Potential tumor cell response includes enhanced cell proliferation, 
proteolytic activity, migration and invasion. Potential EC response contributes with tumor 
neovascularization and loosing of permeability properties of the microvascular barrier at the 
tight and gap junctions, and adherens junctions (cadherins) 
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2.3 Cadherins and selectins 
E-cadherin is a protein with extracellular, transmembrane and cytoplasmic domains. The 
surface glycoprotein of E-cadherin acts to connect neighboring cells whereas the cytoplasmic 
tail is noncovalently linked to the actin cytoskeleton via catenins. E-cadherin not only acts as 
molecular glue, but also mediates intracellular signaling through β-catenin. Growth factor 
signaling pathways are important in regulating the cadherin-catenin complex through 
phosphorylation and dephosphorylation of β-catenin. Melanoma cells induce vascular VE-
cadherin junction disassembly through heterotypic contact with human umbilical vein ECs 
(HUVEC) in co-culture. Melanoma-induced VE-cadherin disassembly and upregulation of 
p38 MAP kinase in ECs are regulated by both soluble factors from melanomas, particularly 
interleukin IL-8, IL-6, and IL-1β, VEGF, sVEGFR-1, bFGF, and through vascular cell 
adhesion molecule-1 (Khanna et al., 2010; Ruffini et al., 2011). 
During cell-cell adhesion process, attachment of melanoma cells on the endothelium induces 
a twofold increase in transmembrane N-cadherin expression in melanoma cells and the 
redistribution of N-cadherin to the heterotypic contacts. Whereas N-cadherin and β-catenin 
colocalize in the contact regions between melanoma cells and HMVEC during the initial 
stages of attachment, β-catenin disappears from the heterotypic contacts during 
transmigration of melanoma cells. Immunolocalization and immunoprecipitation studies 
indicate that N-cadherin becomes tyrosine-phosphorylated, resulting in the dissociation of 
β-catenin from these contact regions. Concomitantly, an increase in the nuclear level of β-
catenin occurs in melanoma cells, together with a sixfold increase in β-catenin-dependent 
transcription (Qi et al., 2005). 
E-selectin and P-selectin, expressed on the EC surface, are considered to play also an 
important role in hematogenous metastasis, and are a marker for proliferating endothelium 
(Ludwig et al., 2004). E-selectin and P-selectin are barely expressed in unstimulated 
endothelial cells. Whereas E-selectin is not expressed in ECs in vivo, unless cells are 
stimulated by an inflammatory cytokine such as IL1β or tumor necrosis factor α, E-selectin 
is expressed in response to cytokines secreted by tumor cells in cancer patients (Kannagi et 
al., 1997). The adhesion of cancer cells to E-selectin expressed by ECs regulates the barrier 
function of these cells. An increase in the activity of endothelial ERK and p38 mitogen-
activated protein kinases, with concomitant enhancement of TEM and migration of cancer 
cells has been observed (Tremblay et al., 2006). 
On the other hand, activation of ERK by E-selectin modulates the opening of interendothelial 
spaces by initiating the activation of Src kinase activities and the dissociation of the VE-
cadherin/β-catenin complex. 
The adhesion of cancer cells to E-selectin expressed by ECs regulates the barrier function of 
these cells. An increase in the activity of endothelial ERK and p38 mitogen-activated protein 
kinases, with concomitant enhancement of TEM and migration of cancer cells, has been 
observed (Tremblay et al., 2006). On the other hand, the activation of ERK by E-selectin 
modulates the opening of interendothelial spaces by initiating the activation of Src kinase 
activities and the dissociation of the VE-cadherin/β-catenin complex. 
Melanoma cellular adhesion molecule (MCAM), also known as MUC18, is a membrane 
glycoprotein that functions as a Ca2+-independent adhesion molecule, and mediates 
homotypic and heterotypic adhesion between melanoma cells and ECs, respectively 
(McGary et al., 2002). Up-regulation of receptors and signaling molecules not found on 
melanocytes, but important for melanoma-melanoma and melanoma-EC interactions such 
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as MCAM, N-cadherin and zonula occludens protein-1 (ZO-1), is operative in this context 
(Haass et al., 2005). In addition, transcription factors CREB/ATF-1 and ATF-2 are up-
regulated in these cells. The expression of genes involved in angiogenesis, invasion and 
apoptosis such as bFGF, IL-8, EGF-R, PAR-1 correlates with higher metastatic potential of 
human melanoma cells (Melnikova et al., 2009) (Fig. 1). 
2.4 Chemokines 
Migration of melanoma cells into tissues occurs via a complex and sequential interaction 
between melanoma and ECs. If melanoma cells and the endothelium express pairs of 
tethering molecules such as L-, P-, and E-selectins and their sialylated carbohydrate 
ligands, melanoma cells flowing through the blood stream become tethered to a vessel 
wall and can roll along the endothelium. Subsequently, integrin activation and cell arrest 
in the endothelium are induced by chemokines, soluble or matrix-bound chemotactic 
factors produced by the surrounding tissue or ECs, and presented on the luminal surface 
of the vessel wall. EC-secreted chemoattractants can induce, in fact, melanoma cell 
chemotaxis. 
A large number of chemokines have been discovered in recent decades. CXC chemokines 
are heparin-binding proteins that display unique disparate roles in the regulation of 
angiogenesis. Members (CXCL1-8) that contain the ERL motif bind to CXC chemokine 
receptor 2 (CXCR2) on endothelium and are angiogenic (Vandercappellen et al., 2008). For 
example, a serial mechanism for the maintenance of angiogenic microenvironment 
encompasses VEGF activation on ECs which can lead to upregulation of antiapoptotic 
molecule, Bcl-2, that in turn promotes the expression of EC-derived CXCL8; the upregulated 
expression of CXCL8 functions in an autocrine and paracrine manner to maintain the 
angiogenic EC phenotype. The growth-related oncogene (GRO) subgroup of chemokines 
(CXCL1/GROα, CXCL2/GROβ, CXCL3/GROγ) was originally identified from culture 
supernatant of melanoma cell lines (Richmond & Thomas, 1988), and acts as autocrine 
growth factor for the melanoma and other tumors (Fig. 1). 
Some chemokines such as IL-8, RANTES (CCL5), MIP-1β (CCL4), and IP-10 (CXCL10) 
selectively attract melanoma cells. Chemotactic response to IL-8 is mediated by  
CXC-chemokine receptor CXCR1 (Ramjeesingh et al., 2003). CXCL1,2,3 are important 
mediators of tumorigenesis related to melanoma. CXCR1 or CXCR2 are stably 
overexpressed in human melanoma cell lines, and CXCR1- or CXCR2-induced modulation 
of the melanoma cell proliferation and migration was observed to be mediated through 
stimulated ERK1/2 phosphorylation (Singh et al., 2009) and PKA, PI3K/Akt, PKC, 
Ras/Raf/MEK/JNK/p38/ERK2 enhanced activities (Strieter et al., 2006). On the other hand, 
tumor ECs secrete high levels of CXCL9 in all, and CXCL10 in most melanoma metastases 
(Amatschek et al., 2011). In this context, tumor-derived chemokines further determine influx 
of ECs into the tumor. In HUVEC, GRO-α markedly increases metalloproteinase MMP-1 
and -2, VEGF, angiopoietin-2, CD31, and receptor KDR and CXCr2 (Caunt et al., 2006). 
Chemokines deliver downstream signals via heterotrimeric G-protein-coupled receptors, 
and not only increase the affinity of integrins for their ligands, but also stimulate cell 
motility. CXCL12/CXCR4 is the most commonly expressed chemokine/chemokine receptor 
pair in human cancers, in which it regulates cell adhesion, extravasation, metastatic 
colonization, angiogenesis, and proliferation. All of these processes require activation of 
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In a human melanoma cell line, PI3Kγ regulates tumor cell adhesion in response to CXCL12 
stimulation, through mechanisms different from those involved in cell invasion. Data 
indicate that, following CXCR4 activation after CXCL12 binding, the invasion and adhesion 
processes are regulated differently by distinct downstream events in these signaling 
cascades (Monterrubio et al., 2009). 
3. Extracellular matrix degradative enzymes (heparanase, metalloproteinases) 
and oxidative stress 
Heparan sulfate proteoglycans (HSPGs) are ubiquitous molecules present as cell surface 
components anchored in the plasma membrane, as ingredients of the insoluble ECM or as 
soluble molecules present in ECM and serum (Lander & Selleck, 2000). Cell surface HSPGs 
play a role in the cell signaling integration and influence biological processes by interacting 
with a large number of physiologically macromolecules (e.g., growth factors, chemokines) that 
regulate cell behavior in normal and pathological processes (Iozzo & San Antonio, 2001). 
It has become increasingly clear that heparan sulfates (HSs) and HSPGs play important roles 
in regulating disease processes including tumor progression and invasion (Sasisekharan et 
al., 2002). Metastatic melanomas show aberrant modulation of several key HS biosynthetic 
enzymes such as 3-O-sulfotransferase and 6-O-sulfotransferase, and also catabolic enzymes 
such as HSulf-1, HSulf-2 and heparanase (HPSE), the mammalian endoglucuronidase whose 
promotion activity of aggressive tumor behavior has been widely implicated in cancer 
metastasis (Arvatz et al., 2011). In ECs, heparanase colocalizes with lysosomes predominately 
around the nucleus, and angiogenic factors cause its dispersion towards the plasma 
membrane for subsequent secretion. Extracellular heparanase, secreted by melanoma and 
ECs, is able to cleaving heparan sulfate side chains of HSPGs including syndecans, thus 
contributing to degradation of ECM and basement membrane underlying epithelial and 
ECs, and cell invasion. The enzyme produces HS fragments which are biologically active, 
for example, able to bind growth and angiogenic factors. On the other hand, heparanase 
contributes to melanoma metastasis and angiogenesis by generating bioactive HS from the 
cell-surface (Raman & Kuberan, 2010; Roy & Marchetti, 2009). Inhibition of HPSE-1 
expression inhibits tumor cell invasion by metastatic melanoma cells (Roy et al., 2005). 
HS sequence and length are regulators of fibroblast growth factor-2 (FGF-2) activity, an 
important mediator of melanoma angiogenesis and progression (Herlyn, 2005). HPSE is able 
to both enhance and inhibit FGF-2 binding and activity in an HPSE concentration-
dependent manner. Cell exposure to HPSE or to HPSE-degraded HS modulates FGF-2-
induced angiogenesis in melanoma (Reiland et al., 2006). In addition, heparin and HS have 
profound effects on VEGF165 function (Robinson & Stringer, 2001). Two heparin-binding 
sites of the VEGF165 dimer interact simultaneously with highly sulfated S-domain regions of 
the HS chain linked through a stretch of transition sequence (Robinson et al., 2006). 
Treatment with exogenous heparanase downregulated brain metastatic melanoma (BMM) 
cell invasion. Extracellular HPSE modulates BMM cell signaling by involving syndecans 
(SDCs)1/4 carboxy terminal-associated proteins and downstream targets. Small GTPase 
guanine nucleotide exchange factor-H1 (GEF-H1) is a new component of a SDC signaling 
complex that is differentially expressed in BMM cells compared to corresponding 
nonmetastatic counterparts. Knockdown of GEF-H1, SDC1, or SDC4 decreased BMM cell 
invasiveness and GEF-H1 modulated small GTPase activity of Rac1 and RhoA in 
conjunction with heparanase treatment (Ridgway et al., 2010). 
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Notably, although heparanase inhibitors attenuated tumor progression and metastasis, 
other studies revealed that heparanase also functions in an enzymatic activity-independent 
manner. Thus, inactive heparanase was noted to improve adhesion and migration of 
primary ECs and to promote phosphorylation of signaling molecules such as Akt and Src, 
facilitating gene transcription (i.e. VEGF) and phosphorylation of selected Src substrates (i.e. 
VEGF receptors). The concept of enzymatic activity-independent function of HPSE had 
gained substantial support by the recent identification of the HPSE C-terminus domain as 
the molecular determinant behind its signaling capacity (Barash et al., 2010). 
Among enzymatic-independent functions are the induction of Akt/PKB phosphorylation 
noted in endothelial- and tumor-derived cells, stimulation of PI3K- and p38-dependent EC 
migration, and upregulation of VEGF, all responses contributing to its potent pro-angiogenic 
activity. Protein domains of heparanase required for signaling are not identified to date, nor 
are identified heparanase binding proteins/receptors capable of transmitting heparanase 
signals. The possible function of mannose 6-phosphate receptor (MPR) and low-density 
lipoprotein-receptor related protein (LRP), recently implicated in cellular uptake of 
heparanase, as heparanase receptors mediating Akt phosphorylation, has been examined. 
HPSE addition to MPR- and LRP-deficient fibroblasts elicited Akt activation indistinguishable 
from control fibroblasts. In contrast, disruption of lipid rafts abrogated Akt/PKB 
phosphorylation following HPSE addition. These results suggest that lipid raft-resident 
receptor mediates heparanase signaling (Ben-Zaken et al., 2007). 
Cancer metastasis is accompanied by orchestrated proteolytic activity executed by array of 
proteases such as matrix metalloproteases (MMP). The repertoire of the cellular molecules 
expressed on the cell surface (E-cadherin silencing, N-cadherin and VCAM-1, ICAM-1 
overexpression, melanotransferrin and integrin αvβ3 upregulation, CD9 tetraspanin 
redistribution) may promote invasion and metastasis through an interaction with increased 
MMP-2 (Fig. 1). This MMP plays a role in assisting melanoma cells to degrade type IV 
collagen in the basement membrane, an early step in metastasis cascade that promotes 
tumor cell disassociation and invasion. One of the mechanism by which integrins 
modulate tumor progression is the transduction of signals regulating expression of matrix-
specific MMP (Munshi & Stack, 2006). α5β1 integrin, a fibronectin-binding specific integrin, 
interacts with MMP-2 collagenase on the surface of SKMEL-147 human melanoma cells, 
suggesting that it controls cell invasion via regulation of MMP-2 collagenase expression. 
This control can occur either through signaling pathways involving PI3K, Akt, ERK protein 
kinases and the c-Jun, or via direct recruitment of MMP-2 to the cell surface (Morozevich et 
al., 2009). 
While the importance of specific degradative proteases such as MMPs is well documented, 
there is some evidence that reactive oxygen species (ROS) are also involved in tumor-cell-
endothelial interactions. Recent observations have demonstrated that neoplastic cells, in 
particular melanomas, produce increased levels of ROS and pyrrolic end products of lipid 
oxidation, and thus themselves have the capability to damage ECs (Sander et al., 2003; West 
et al., 2010; Wittgen & van Kempen, 2007). 
4. Pericytes 
In tumor vascular bed, proliferating ECs and pericytes are detected, but angiogenesis is 
present with characteristic and significant differences among the malignant tumor types. 
Particularly significant are the varying degrees of pericyte recruitment indicating differences 
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in the functional status of the tumor vasculature. In addition, they show multiple 
abnormalities, i.e. loose association with ECs, extended cytoplasmic processes deep into the 
tumor tissue and altered expression of marker proteins (NG2, 3G5), vessel leakiness 
(Morikawa et al., 2002). The regulatory role of pericytes in angiogenesis is very poorly 
appreciated at molecular level, despite the fact that tumor metastasis invasion and 
intratumoral vessel growth need the perturbation of pericyte-EC cell-cell interactions and 
promotion of pericyte invasion during neovascularization by ECM degradation. Paracrine 
PDGF production by B16 mouse melanoma stimulates pericyte recruitment to tumor 
vessels, suggesting that pericyte abundance influences tumor cell apoptosis and tumor 
growth (Furuhashi et al., 2004). 
5. Factors released by melanoma cells (VEGF, bFGF, PDGFα/β-TGF, IL-1, IL-8) 
To promote angiogenesis, tumors secrete a variety of growth factors such as VEGF, bFGF, 
platelet-derived growth factor (PDGF) that induce EC activation in nearby vessels. VEGF is 
a major inducer of angiogenesis in tumors. In human melanoma cell lines, VEGF and bFGF 
expression, heterogeneous in levels, was observed (Danielsen & Rofstad, 1998). Melanoma 
and colorectal carcinoma cells express functional EGF/TGF- α receptors, and produce TGF-
α, indicating that this growth factor is synthesized for autocrine stimulation. By screening a 
panel of 8 primary and 21 metastatic melanoma cell lines for constitutive secretion of 
cytokines, it was found that melanomas expressed bioactivity for transforming growth 
factor (TGF- β) (8/25 lines) and IFN (7/12), but not IL-2. Immunoassays detected interleukin 
IL-1α (4/25), IL-1β (12/25), IL-6 (13/29), IL-8 (29/29), TGF-β2 (5/12) and GM-CSF (11/29), 
but not IL-3, IL-4, TNF-α, or IFN-γ. IL-8 was produced by all lines tested. The data 
demonstrated that cultured melanoma cells produce a variety of cytokines which are 
potentially capable of influencing tumor growth in vivo (Bennicelli & Guerry, 1993). In 
tissue culture of choroidal melanomas and two established skin melanoma cell lines, high 
secretion of IL-6 was detectable in choroidal melanoma cultures, but not in the cell lines. IL-
8 secretion was found in all melanoma cultures (Fig. 1). However, IL-10 was only secreted 
by one skin melanoma cell line and in choroidal melanoma cell cultures. Secretion of bFGF 
by choroidal melanomas was higher than by other cell lines. No differences were seen in the 
amount of TGF-β1 produced by melanoma cells (Enzmann et al., 1998). Secretion of 
interleukin-1 receptor antagonist (sIL-1ra), IL-6, IL-8, IL-10, TGF-α, TGF-β, VEGF, PDGF, 
bFGF, angiopoietin-1 and angiopoietin-2 was found in seven human uveal melanoma cell 
lines (Ijland et al., 1999).  
In a study of a large number of uveal tumors, it was observed that while most tumor cells 
expressed bFGF at the protein level (89%), relatively few (22%) expressed VEGF. All 20 
tumors tested by RT-PCR contained mRNA for both bFGF and VEGF. Co-culture 
experiments using an ATP based bioassay showed that uveal melanomas could support the 
growth of a rat brain endothelial cell line and HUVEC (Boyd et al., 2001). VEGF receptors 
VEGFR1, VEGFR2 and neurophilin-1 are expressed in A375 melanoma cells. Overproduction 
of VEGF165 concomitantly expressed with its receptors favors cell growth and survival of 
melanoma cells through MAPK and PI3K signaling pathways (Graells et al., 2004). 
PDGF receptor signaling participates in the stimulation of tumor angiogenesis. PDGF-BB is 
produced by ECs, and PDGFR-β is expressed by mural cells, including pericytes. PDGF-BB 
is produced by most types of solid tumors, and PDGF receptor signaling participates in 
various processes, including autocrine stimulation of tumor cell growth and recruitment of 
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tumor stroma fibroblasts. Furthermore, PDGF-BB-producing tumors are characterized by 
increased pericyte abundance and accelerated tumor growth (Suzuki et al., 2007). 
By using an antibody-based proteomics strategy, galectin-1, a protein member of the group 
of lectins that bind to β-galactosides, was identified as protein with enhanced expression in 
cells from the melanocytic lineage and cancer tissues, and as a proangiogenic factor 
(Bolander et al., 2008). Indeed, in invasive B16 melanoma supernanants, proteomic analysis 
allowed the identification of 18 differential proteins, among which the proteins with a 
higher concentration, lactate dehydrogenase B, M2 pyruvate kinase, cathepsin D, and 
galectin-1 (Rondepierre et al., 2010). Uptake of galectin-1 by cultured endothelial cells 
specifically promotes H-Ras signaling to the Raf/MAP kinase/Mek/ERK cascade and 
stimulates EC proliferation and migration (Thijssen et al., 2010). 
6. Cell co-culture models 
The cross-talk between melanoma and ECs has been assessed in in vitro co-culture models 
in which signal transduction mechanisms can be closely studied. ECs are able to 
communicate with tumor cells through gap junctions, allowing cytosolic exchange of 
peptides and other small molecules (Saito-Katsuragi et al., 2007). Melanoma cells seeded on 
confluent lymphatic endothelial cells (LECs) were able to adhere by pseudopodia, and to 
induce endothelial junction dissolution and retraction. The passage of the tumor cells 
through the opened gap and the migration under LECs suggest that tumor cells could 
metastasize through the lymphatic vessel by destroying intercellular junctions (Ding Z. et 
al., 2005). 
An interesting work demonstrated that B16 melanoma cells, together with Lewis lung 
carcinoma cells, produce the lipoxygenase metabolite 12(S)-HETE during in vitro interaction 
with CD3 microvascular ECs, which in turn induce EC retraction (Honn et al., 1994). These 
results suggest that 12(S)-HETE synthesis during tumor cell–endothelial cell interactions 
may represent a key contributory factor in cancer metastasis. 
The supporting role of soluble pro-angiogenic cytokines such as bFGF and VEGF in the 
endothelial growth and their expression by co-cultured melanomas have been well 
described. Rat brain and human EC lines show significant enhancement of cell growth by 
48–120 h of co-culture with melanoma cells without cell–cell contact (Boyd et al., 2002). In a 
co-culture system based on transwell indirect model, bone-marrow-derived mesenchymal 
stem cells (BMSCs) acquired endothelial phenotype and expressed VEGFR-1, VEGFR-2 and 
factor VIII after co-culture with B16 cells (Sun et al., 2008). 
Treatments with angiogenesis inhibitors markedly suppressed in vitro tube formation by 
human endothelial cells and HUVEC, whereas tubular network formation by human 
melanoma MUM-2B and C8161 cells was relatively unaffected. The differential response of 
the two cell types was probably due to higher mRNA and protein endothelial expression for 
α5 integrin and heparin sulfate proteoglycan 2 than melanoma cells (van der Schaft et al., 
2004). On the other hand, analyses of malignant melanomas in co-culture with 
microvascular ECs revealed a strong expression of bone morphogenic proteins and their 
capability to induce tube formation and migratory efficiency (Rothhammer et al., 2007). 
A critical role in the regulation of melanoma-endothelial intercellular communication is 
interpreted by neuropilin-2 (NRP2), a co-receptor for VEGF and the semaphorin (SEMA) 
families. Overexpression of NRP2 in primary human ECs promoted cell survival induced by 
VEGF-A and VEGF-C. In contrast, SEMA3F, another ligand for NRP2, was able to inhibit 
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human EC survival and migration induced by VEGF-A and VEGF-C (Favier et al., 2006). In 
melanoma cells, NRP2 is upregulated in a two-dimensional co-culture systems of melanoma 
and ECs, suggesting that NRP2 assists melanoma cells in EC recruitment towards the 
development of a functional new vasculature, thus enhancing melanoma survival and 
providing potential routes for metastasis (Stine et al., 2011). 
Studies using two-dimensional melanoma-EC cultures have greatly advanced our knowledge 
of angiogenesis, and will continue to be used extensively. Furthermore, results generated in 
two-dimensional cultures can be furthered by the use of three-dimensional model systems 
that mimic the natural tumor environment and may result in the development of treatments 
with better therapeutic outcomes. Collagen-implanted melanoma spheroid consists of cell 
aggregates grown in a collagen matrix. Melanoma spheres mimic an in vivo tumor with cells 
having differing access to oxygen and nutrients depending on position in the spheroid. 
Similar to a tumor in vivo, the proliferating cells are found on the outside of the spheroid, 
while the innermost cells have downregulated ERK and cyclin-dependent kinase activity 
(Haass et al., 2008). 
In a 3-D co-culture system, human ECs and GFP-expressing melanoma cells formed distinct 
tumor clusters with integrated endothelial networks when seeded on tumor-derived 
extracellular matrix. In contrast, an entirely different phenotype was exhibited when the 
tumor matrix was replaced with collagen, suggesting that the extracellular matrix impinges 
on cellular function, possibly by an Akt-mediated mechanism (Sengupta et al., 2004). 
Furthermore, in melanoma cell lines co-cultured with vascular ECs in three dimensional 
spheroids, VEGF-induced angiogenesis was inhibited after treatment with resveratrol. Τhis 
effect was associated with increased melanoma cell expression of p53 and matrix protein 
TSP1, as well as decreased hypoxia-driven expression of hypoxia inducible factor-1α, and 
inhibition of VEGF production (Trapp et al., 2010). 
7. Phospholipase A2 activation 
Cytosolic phospholipase A2 (cPLA2), which regulates the provision of arachidonic acid (AA), 
cyclooxygenase-2 (COX-2), and prostaglandin E2 release, is highly upregulated in 
angiogenic ECs during tumor progression (Wendum et al., 2005), promoting integrin αvβ3-
mediated EC adhesion, spreading, and angiogenesis through prostaglandin cAMP-PKA 
dependent activation of the small GTPase Rac (Bogatcheva et al., 2005). Phospholipases A2 
are a diverse group of enzymes that catalyze the hydrolysis of the sn-2 substituent from 
glycerophospholipid substrates to yield a free fatty acid and 2-lysophospholipid acceptors 
(Balsinde et al., 2002). They are the rate limiting step for the AA production from membrane 
phospholipids, which in turn is the major precursor to prostaglandins, leukotrienes, and 
hydroxyeicosatetraenoic acids (via the cyclooxygenase, lipoxygenase, and epoxygenase 
pathways, respectively) that increase cell proliferation in response to various agonists in 
different cell types (Anfuso et al., 2007; Balsinde et al., 2002; Chakraborti, 2003; Lupo et al., 
2002).  
Among the PLA2s is an 85 kDa cPLA2 that requires Ca2+ for catalysis, and a calcium 
independent PLA2, iPLA2β, for which several potential functions have been proposed, 
including a housekeeping role in phospholipid remodeling and a signaling role in cell 
growth, apoptosis, secretion, inflammation, and oxidant-induced cell injury (Chakraborti, 
2003). A number of observations that iPLA2 has a functional role in cellular signaling in 
addition to its roles in AA release and phospholipid remodeling have been reported (Akiba 
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& Sato, 2004). iPLA2 mediates the phosphorylation of transcription factors through a PKA-
dependent pathway (Martinson et al., 2003). 
We recently demonstrated that human melanoma cells highly express PLA2, COX-1/COX-2, 
and produce higher levels of prostaglandins than normal melanocytes; this response 
correlated with higher proliferation rate and was blocked by specific inhibitors of PLA2 and 
cyclooxygenase (Scuderi et al., 2008). It was also demonstrated that in vitro ECs/ melanoma 
co-culture or EC cultures enriched with melanoma conditioned medium (CM) recapitulate 
the signals that arise from the relationship between these cell types in an intact vascularized 
tumor (Anfuso et al., 2009). In that study, it was performed cell culture experiments in 
which CMs prepared from two human melanoma lines, SKMEL-28 and OCM-1, were 
incubated with quiescent GP8.3 rat brain immortalized ECs, in order to study the CM effect 
on EC proliferation and migration and on the expression of phospholipases, and activation 
of the ERK1/2 and PI3K/AKT pathways. Melanoma CMs significant increased endothelial 
AA release versus control unstimulated cells. This result indirectly demonstrated that 
melanoma CM-stimulated AA release in ECs was mediated by activation of phospholipase 
A2 enzymes. The use of the specific iPLA2 inhibitor, bromoenol lactone, allowed to 
discriminate between the c- and iPLA2 activity contribution. A major contribution of cPLA2 
enzyme activity in mediating AA release of melanoma CM-stimulated ECs was found. 
Additional findings suggested that the mitogen-activated protein kinase ERK1/2 and PI3K 
are involved in the signaling pathways that mainly activate cPLA2. Furthermore, it was 
observed, by confocal microscopy, activation of cPLA2 in perinuclear and membrane regions 
of ECs grown in CM-stimulated cultures, suggesting that cPLA2 and its downstream 
products, after long-lasting stimulation of ECs by melanoma CMs, play significant roles in 
nuclear functions such as regulation of gene expression and cell proliferation. 
In order to clarify the roles of cPLA2 and iPLA2 in ECs stimulated by melanoma in in vitro 
models (Fig. 2), recently we were able to demonstrate that the non-contact presence of 
melanoma cells in EC co-cultures, in the absence (double co-cultures) or presence (triple  
co-cultures) of microvascular pericytes, increased cPLA2 and iPLA2 protein expression (Fig. 
3). In cultured ECs, 48 hour exposure to melanoma cells significantly increased cPLA2 
expression, with a 2.7-fold (p<0.01) and 1.6-fold (p<0.01) increase in iPLA2 total protein, 
respectively (Fig. 3 A,B). Furthermore, melanoma-stimulated GP8.3 ECs showed an increase 
in the constitutive phosphorylated form of cPLA2 by 8.3-fold (p<0.01) compared to 
unstimulated control cells. Thus, the increase of cPLA2 synthesis and phosphorylation  
(p-cPLA2/cPLA2 ratio from 0.20 to 1.66 for melanoma-stimulated ECs) may support an 
increase in cPLA2 activity. 
Since endothelial PKCα might be involved in stimulated endothelial cPLA2 activity and 
p42/p44 MAPK phosphorylation by melanoma cells via the Raf-MEK pathway, we further 
evaluated the PKCα and ERK1/2 protein expression and activation. Tumor cells had no 
significant effect on total PKCα expression compared with unstimulated control ECs (Fig. 
3C); however, the presence of melanoma did induce a 2.1-fold (p<0.01) increase in 
phosphorylated PKCα form expression in ECs, with basal phosphorylation levels around 
70% in unstimulated ECs. In addition, as shown in Fig. 3D, the presence of melanoma cells 
in EC co-cultures did not induce changes or increases in endothelial total p42/p44 MAPK 
(ERK1/2, double band) protein expression. On the contrary, melanoma-stimulated GP8.3 
cells showed an increase in phosphorylated form of ERK1/2 by 3.1-fold (p42, p<0.01), 
compared to control unstimulated ECs grown alone. These data indicate that in ECs the 








Fig. 2. Scheme of different Transwell systems for co-cultures of endothelial cells (ECs) and 
melanoma derived cells in monolayers. Immortalized rat brain endothelial cells (GP8.3) 
were fed with F10 HAM’s medium supplemented with 10% FBS, 80 μg/ml heparin, 2 mM 
glutamine and antibiotics. Cultures of pericytes isolated from microvessels were prepared 
from bovine retinas as described previously (Lupo et al., 2001). The isolated cells were then 
cultured in DMEM supplemented with 2 mM glutamine, 10% FBS and antibiotics. COLO38 
is a malignant melanoma cell line which expresses the MPG antigen and was grown in 
RPMI medium containing 2 mM glutamine, 10% FBS and antibiotics. Culture plates and 
inserts were coated on the upper and the bottom side with collagen. (a) EC or pericyte 
monolayers (1 and 2). (b) Melanoma cells are placed on the bottom of the wells, while ECs 
are present in the semipermeable filter insert (1). Pericytes are seeded on the lower side of 
the membrane insert, while ECs are present in the apical side of the filter insert (2). (c) 
Melanoma cells are seeded on the lower side of the membrane filter (1 and 2), and then ECs 
(1) or pericytes (2) are seeded in the upper compartment. In the third system, pericytes are 
seeded on the lower side of the filter, and then ECs are seeded in the upper compartment 
(3). In all systems, cells on both sides are exposed to conditioned medium from the cell type 
growing on the bottom of the wells. In panels (b)-2 and (c)-3, pericytes were first plated on 
the outside of the membrane filter (80,000 cells). 4 hour after, the inserts were placed into 
six-well plates with the culture medium. ECs were plated on the top surface of the same 
inserts (80,000 cells) on which pericytes have been plated two days before. Three days after, 
the inserts were placed into wells where COLO 38 melanoma cells have been already 
cultured for at least 2 days. As controls, ECs were also cultured with either COLO38 cells or 
pericytes alone (double co-culture) and without any other cell type. All control- and three 
cell type-cultures [panel (a)-1, panel (b)-1,2, panel (c)-3] were fed for 24 h in a serum-free 
DMEM-F10-HAM’s (1:1) plus glutamine medium 
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Fig. 3. Western blot analyses of cPLA2, calcium-independent intracellular phospholipase A2 
(iPLA2), total extracellular signal-regulated kinases (ERK1/2), PKCα, COX-1/-2 and 
phosphorylated forms of ERK1/2, cPLA2 and PKCα protein expression in GP8.39 
EC/bovine retinal pericyte (PC) co-cultures in the presence of COLO38 melanoma cells 
(triple co-culture). In the in vitro model of control blood brain barrier or tumor-conditioned 
blood brain barrier (see Fig. 2, panel b-2, c-3), 48 hours after incubation ECs were scraped 
from the insert with a rubber policeman, and lysates were resolved by SDS/PAGE (Lupo et 
al., 2005). Expressed proteins were independently revealed with cPLA2, p-cPLA2, PKCα, 
COX-2 or p-ERK monoclonal antibodies, and iPLA2, p-PKCα, COX-1 or ERK1/2 polyclonal 
antibodies. The ratios of the band intensities, phospho-cPLA2/total cPLA2 and phospho-
PKCα/total PKCα, are indicated. The values (bar graphs) expressed as arbitrary 
densitometric unit (a.d.u.), were obtained by the reading of blots using the Image J program, 
and are means ± S.E.M. from three independent experiments. Representative gels are 
shown; statistically significant differences by pairwise Student’s t-test are indicated by 
asterisks (*p<0.05, **p<0.01), comparing EC/PC cultures in presence of COLO38 with EC 
monoculture or EC/PC co-cultures 
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ERK1/2 pathway is involved in enhanced AA liberation and GP8.3 EC proliferation 
(sequential activation of ERK1/2 and cPLA2) induced by melanoma cell presence in the 
culture medium.  
Because COX-1 and COX-2 govern the rate limiting step in the conversion of AA to its 
downstream prostanoid effectors, we also evaluated COX-1 and COX-2 expression in ECs in 
response to the presence of COLO38 cells in co-cultures. Melanoma-stimulated ECs, for 48 h, 
significantly expressed COX-2 total protein at levels higher (3.3-fold; p<0.01) than control 
unstimulated EC cultures (no additions) (Fig. 3E). Melanoma cells did not induce any 
change in COX-1 protein expression. These results indicate substantial contribution of COX-2 
activity, chiefly stimulated by growth factors such as VEGF, to endothelial prostanoid 
synthesis, cell proliferation and motility in melanoma-conditioned ECs. 
8. COX-2 and 12-lipoxygenase expression 
COX-1 and COX-2 mediate the rate limiting step in arachidonic acid metabolism. Both in 
vitro and in vivo studies indicate that either COX-2 or COX-1 overexpression upregulates 
angiogenic factors in neoplastic cells and promotes tumor angiogenesis (Tsuji et al., 2001). 
COX-2 promotes integrin αvβ3-mediated EC adhesion, spreading, migration and 
angiogenesis through the prostaglandin-cAMP-PKA dependent activation of the small 
GTPase Rac (Ruegg et al., 2004). 
There are several lines of evidence indicating that increased expression of COX-2 plays a 
functional role in the development and progression of malignant epithelial cancer (Kuźbicki 
et al., 2006). COX-2 is expressed in the vasculature of surgically resected human tumors. In 
tumor endothelial cells (TECs) from human melanoma, compared to normal endothelial 
cells (NECs), COX-2 mRNA was upregulated. Cell migration and proliferation were 
suppressed by COX-2 inhibitor NS398 in TECs but not in NECs. The number of 
CD133+/VEGF-2+ cells in the circulation was significantly suppressed by COX-2 inhibition. 
In addition, the number of progenitor marker-positive cells decreased in the tumor blood 
vessels after COX-2 treatment, which suggests that NS398 specifically targets both TECs and 
vascular progenitor cells without affecting NECs (Muraki et al., 2011). 
COX-2 has also recently been reported as a marker of malignant melanoma (MM) in a study 
on 40 archival cases of MM and 35 cases of benign melanocytic lesions. The MM group and 
the benign melanocytic nevi group showed a highly statistically significant difference in the 
intensity of COX-2 expression. Staining intensity in the dermal component of MM cases also 
showed a tendency to increase with increasing tumor depth. By contrast, the intensity of the 
dermal component in the melanocytic nevi group decreased with increasing depth as the 
nevus cells matured from type A to type C cells (Minami et al., 2011). Furthermore, Kaplan-
Meier curves illustrated a significant correlation between staining intensity and disease-
specific survival (Becker, 2009). 
In melanoma cell lines, A375 and Hs294, overexpression of COX-2 and its metabolite 
prostaglandin E2 (PGE2) receptors promotes cells migration. Treatment of A375 and Hs294 
cells with berberine, an isoquinoline alkaloid, resulted in concentration-dependent 
inhibition of migration of these cells, which was associated with a reduction in the levels  
of COX-2 and PGE2 receptors (EP2 and EP4). Treatment of the cells with  
12-O-tetradecanoylphorbol-13-acetate (TPA), an inducer of COX-2 or PGE2, enhanced cell 
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Specimens from dysplastic nevi, melanoma at different stages and melanoma metastasis 
lymphnodes overexpressed COX-2 compared to normal melanocytes. COX-2 was consistently 
observed in keratinocytes, dermal fibroblasts and inflammatory cells in regions adjacent to 
benign nevi and primary cutaneous melanomas (Goulet et al., 2003). 
Omega-3 and omega-6 PUFA regulated COX-2 mRNA expression and PGE2 production in 
70W, a human melanoma cell line that metastasizes to the brain in nude mice. Additionally, 
PGE2 increased in vitro Matrigel invasion, whereas exposure to PGE3 significantly decreased 
invasion (Denkins et al., 2005). 
12-Lipoxygenase (12-LOX), through its metabolite 12-HETE, has been demonstrated to play 
a pivotal role in experimental melanoma invasion and metastasis. Differences in 12-LOX 
protein expression during the progression of melanoma from human skin melanocytes to 
benign and dysplastic nevi have been found. Melanomas had higher levels of expression 
compared with dysplastic nevi, suggesting that 12-LOX may be an important marker of 
cancer progression (Winer et al., 2002). 
9. Arachidonic acid metabolites: prostaglandins, 12(S)-HETE, leukotrienes 
Lipid mediators derived from the arachidonic acid/5-LOX metabolism have a fundamental 
stimulatory role in melanoma progression associated with inflammation, whereas ω3 
PUFA–derived metabolites have opposite effects (Bachi et al., 2009). Inhibitors of cPLA2, 5-
LOX and COX-2 reduced pulmonary metastasis formation by B16F10 melanoma cells in a 
dose-dependent manner. Importantly, all these inhibitors reduced PAF-induced angiogenesis 
in an in vivo mouse model employing Matrigel of basement membrane injected 
subcutaneously, and also reduced expression of MMP-2 and MMP-9 in the lungs (Jeong et 
al., 2010). Studies of adhesion of a highly metastatic melanoma cell line (WM-1617) 
demostrated that it contains at least two types of close intercellular adhesions: classic focal 
adhesions, and more extensive, irregularly shaped adhesions along lamellipodial edges. 
These adhesions are highly dynamic and highly sensitive to PKCε activation, for example, 
by the 12(S)-HETE. Eicosanoid-induced cell detachment seems to be triggered by 
myristoylated alanine-rich C-kinase substrate (MARCKS) phosphorylation (Estrada-Bernal 
et al., 2009). 12(S)-HETE stimulation of human epithelial carcinoma cell (A431) migration 
involved ERK1/2, PKC, PI3K and Src kinase. Focal adhesion kinase, a key organizer of focal 
cell adhesions, was tyrosine phosphorylated in response of 12(S)-HETE treatment, 
phosphorylation which required Src, but not PKC, PI3K or ERK1/2 enhanced activity 
(Szekeres et al., 2002). 
Prostaglandins (PG) and arachidonic acid metabolites affect melanocyte dendricity, 
melanization, and proliferation (Kashiwagi et al., 2002; Parsad et al., 2002). PGD2, 
leukotriene (LT) B4, LTC4, LTD4, LTE4, thromboxane B2, and 12-(S)HETE increased 
dendricity and tyrosinase in human epidermal melanocytes whereas PGE1, PGF2a, and 6-
ketoPGF1a had no stimulatory effects (Tomita et al., 1992). In B16F10-induced melanoma 
metastasis, PGD2 reduced the protective effect of α-galactosylceramide, an effect depending 
on IFN-γ production by invariant NK T cells (Torres et al., 2008). Nimesulide, a selective 
inhibitor of COX-2 that causes the breakdown of proinflammatory 2-series prostaglandins, 
adversely affected the growth of B16F10 melanoma cells through the induction of 
differentiation, indicating that the antineoplastic activity observed for nimesulide may be 
ascribed to intracellular changes in PG level (Tabolacci et al., 2010).  
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10. Future research 
The events that follow tumor cell adhesion to the endothelium and lead to either the 
estrablishment of secondary tumor colonies or angiogenesis are poorly understood. The 
availability of cell cultures of melanoma cell lines, endothelial cells, pericytes and astrocytes, 
and combinations in co-cultures of three or four cell types in an in vitro multicellular 
systems may greatly contribute to the elucidation of the interplay mechanisms during 
melanoma cell adhesion and migration through endothelial cells and surrounding pericytes 
in blood vessels. Although these triple or quadruple systems are still lacking, it is very likely 
that the use of them may allow in future to discover new and unexpected alterations of the 
gene and protein expression patterns during proinvasive, prometastatic melanoma 
migration as well as endothelial recruitment mediated by intracellular signaling. These 
findings may contribute to the development of new antivascular therapeutic agents that 
target both angiogenesis and tumor cell vasculogenic mimicry. 
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